Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies' Determination against ELISA

• Váldodahkkit: Francisco José Toja-Camba (Dahkki), Laura García-Quintanilla (Dahkki), Lorena Rodríguez-Martinez (Dahkki), Julia Tomine (Dahkki), Francisco Cajade-Pascual (Dahkki), Carolina Feitosa (Dahkki), Irene Zarra-Ferro (Dahkki), Manuel Barreiro- (Dahkki), Jaime González-López (Dahkki), Cristina Mondelo-García (Dahkki), Anxo Fernández-Ferreiro (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: MDPI AG, 2023-11-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

The introduction of point-of-care (POC) assays into clinical practice in patients with inflammatory disease enables on-demand therapeutic decision making. The aim of this study was to compare the POC test Quantum blue (Bühlmann Laboratories) for infliximab (IFX), adalimumab (ADL), and its anti-drug...